Home › Companies › CRVO

CervoMed Inc.

CRVO Rare disease Lead: Phase 2 7 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (5 active programs)

neflamapimod

VX-745

Small Molecule Target: p38α MAPK, p38 MAP kinase alpha, p38α, p38α MAP kinase

Dementia with Lewy Bodies Phase 2 oral Vertex
Non-Fluent Variant Primary Progressive Aphasia Phase 2 oral Vertex
Stroke oral Vertex
Amyotrophic Lateral Sclerosis oral Vertex

neflamapimod

Small Molecule Target: p38α MAPK

Frontotemporal Dementia oral

Biotech Distilled coverage (7)

2026-05-16 UPDATE: CervoMed (CRVO) - The Q1 10-Q Confirms the Countdown
2026-04-27 UPDATE: CervoMed (CRVO) - The Brain Scans Just Got Randomized 🔒 Paid
2026-03-29 UPDATE: CervoMed (CRVO) – Global Regulatory Blessing and Biological Proof at Roth 🔒 Paid
2026-03-21 UPDATE: CervoMed (CRVO) – The 6-Month Warning and the Smoking Gun in Copenhagen 🔒 Paid
2026-03-14 UPDATE: CervoMed (CRVO) – Annual Report Drops 🔒 Paid
2026-03-07 UPDATE: CervoMed (CRVO) – The Bad Batch Fix is In... 🔒 Paid
2025-12-31 CervoMed (CRVO): Scientific Due Diligence for Neflamapimod

Articles open on Substack. Some deep dives are subscriber-only.